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1. Introduction
We would ﬁrst like to express our appreciation to coeditor
David Zucker and the Associate Editor for organizing this
discussion. We also thank the discussants for their comments
on our article. They have raised many excellent points, and
in our response, we only deal with a subset of them.
Geert Molenberghs (M) and John O’Quigley and Philippe
Flandre (OF) accurately describe the methodology in our ar-
ticle as joint regression and association modeling of the sur-
rogate and true endpoints in which a constraint is placed on
the type of data that are used (the “wedge” region). As OF
noted, this constraint leads to the multistate model of Fix and
Neyman (1951). This data structure complicates the standard
estimation procedures that were developed by Burzykowski,
Molenberghs, and Buyse (2005, Ch. 11). However, much of the
model formulation is very similar to what was described there.
The constraints in our approach can be viewed as a diﬀerent
model for the error distribution. Our focus is not on predic-
tions, as advocated by Edward Korn (K), partly because it is
very hard with censored data to estimate the intercept param-
eter in a linear model well without making strong assumptions
(Ying, Jung, and Wei, 1995). K is suspicious of the standard
errors in our semicompeting risks analysis, but our applica-
tion of the methodology to data from Ghosh (2009) yielded
essentially identical answers to those reported there (data not
shown). An implication of the artiﬁcial censoring strategy we
propose here is that we are throwing away information on
recurrences. Consequently, the standard errors for the treat-
ment eﬀects on the surrogate endpoint will increase in our
approach relative to approaches that do not throw away that
information (e.g., the analyses in Table 1 of K’s discussion).
An implication of the semicompeting risks approach will be
that the magnitude of the treatment eﬀect on the surrogate
endpoint will be less than or equal to that on the true end-
point because of the wedge contstraint.
Vance Berger, Grant Izmirlian, and Diana Knoll (BIK) and
K criticize us with respect to composite endpoints. There are
two issues here. The ﬁrst is whether or not composite end-
points should be used for assessing treatment eﬀects in clinical
trials. BIK and K strongly advocate for composite endpoints
such as disease-free survival in oncology trials. Since disease-
free survival is arguably a meaningful clinical endpoint, we
agree with BIK and K’s point if the goal is simply to un-
derstand the treatment eﬀect. However, a second goal is at-
tempting to understand the association between the surrogate
endpoint with the true endpoint. As we discussed in the arti-
cle, this is problematic if the surrogate endpoint is a compos-
ite endpoint that uses information on the true endpoint. In
the context of the motivating colorectal cancer example, we
are arguing that recurrence and death are separate processes.
One can interpret our modeling strategy as a model for the
process that gave rise to the data, rather than a model for
the observed data. In modeling the biology, in this context,
it is useful to recognize that recurrence is not a spontaneous
event. It occurs because the cancer is regrowing and reaches a
size where it is detected. From this perspective, there is some
rationale for considering when the cancer would have grown
to such a size to be detected had not the patient died from
something else. K says patients might die from their disease
without having progression or having it observed. That is con-
text dependent and pretty rare in the cancer clinical trials we
analyze.
OF and K advocate the use of proportional hazards (PH)
models in their discussions. Since we were focusing on estima-
tion using the wedge constraint, PH models were not available
to us. The recent work of Xu, Kalbﬂeisch, and Tai (2010),
discussed by OF, allows for proportional hazards models for
S and T in the semicompeting risks setting. The type of R2
that OF describe comes from a comparison of models for T |Z
and T |S, Z . It is not at all straightforward to calculate this
C© 2011, The International Biometric Society 1
2 Biometrics
Table 1
R2 values for recurrence in the colorectal cancer data
Study R2
C01 0.51
C02 0.38
C03 0.55
C04 0.52
C05 0.48
C06 0.42
C07 0.38
INT-0035 0.52
NCCTG 784852 0.57
NCCTG 874651 0.54
NCCTG 894651 0.56
NCCTG 914653 0.53
Note: The method of Nagelkerke (1991) was used to calculate R2.
In particular, two PH models were compared. Both had age (log trans-
formed), stage, and treatment as covariates; one included recurrence
as a time-dependent covariate, the other did not. The baseline hazard
function was modeled using a Weibull distribution.
quantity here because of two reasons. The ﬁrst is that includ-
ing S as a covariate, in conjuction with the constraint that
S < T , will complicate estimation. Second, provided one could
develop a valid method for estimation in the model for T |S,
Z with S < T , calculating an R2-type measure poses its own
issues. Guidance for constructing such measures would come
from previous proposals to create likelihood ratio-type statis-
tics from estimating equations (e.g., Li, 1993).
OF were interested in the R2 values for our example. We
show them in Table 1 for the colorectal cancer data in which
parametric Weibull PH models are ﬁt, along with adjustment
for stage, age (log transformed), and treatment. The method
of Nagelkerke (1991) for calculating R2 was used. The values
range between 0.38 and 0.56, compared with the R2 value of
0.69 that OF obtained in their example. The question remains
of how to set guidelines for using the R2 value in deciding
whether to use the surrogate marker.
M makes a push for performing sensitivity analyses in our
modeling procedures. We agree this is an important task and
area for future research. He also asks about the potential
for causal interpretations of the parameters that we have es-
timated. Using the structural modeling framework of Pearl
(2001), we (Ghosh, Elliott, and Taylor, 2010) have recently
shown that the relative eﬀect (i.e., ratio of the two regression
coeﬃcients) can be interpreted as a causal parameter in the
linear case. There has been recent work on framing the surro-
gacy problem in the potential outcomes framework (Gilbert
and Hudgens, 2008; Li, Taylor, and Elliott, 2010). Attempt-
ing to incorporate the semicompeting risks data structure into
the potential outcomes framework is more challenging. Sup-
pose we deﬁne the potential outcomes {S∗i (1), S∗i (0), T ∗i (1),
T ∗i (0)}, i = 1, . . . , n, where {S∗i (Z), T ∗i (Z)} denotes the joint
potential outcome for time to the surrogate and true end-
points, respectively, for the ith individual if assigned treat-
ment Z , Z = 0/1. Then causal estimands are deﬁned to be
within-individual contrasts in T ∗ and S∗. Frangakis and Rubin
(2002) deﬁned the concept of principal stratiﬁcation, in which
within-individual contrasts for T ∗ are considered conditional
on S∗. The problem with the semicompeting risks approach
is that S∗ might not be well deﬁned if the person experiences
the true endpoint but not the surrogate endpoint. This has
been referred to by Zhang and Rubin (2003) as “truncation
by death.” While the potential outcomes framework might
not allow for well-conceptualized causal estimands with semi-
competing risks data, this is not the only model for causality
that exists in the literature. In particular, econometricians
work with so-called structural selection models (Abbing and
van den Berg, 2003), and such a modeling framework might
allow for better incorporation of semicompeting risks data.
Of course, “causal estimand” has a diﬀerent meaning using
these models relative to the potential outcomes framework.
This research is currently under investigation.
We broadly agree with much of what the discussants pro-
posed regarding trial-level meta-analysis. K advocates pre-
diction, but as noted before, that is not straightforward in
our modeling scheme with censoring present. In our example,
we combined treatment arms despite well-documented evi-
dence of heterogeneity in the diﬀerent groups. We note that of
14,246 initial subjects, there are 56 and 48 subjects with time
to recurrence and time to death equaling zero, all of which
are censored, so this represents a very small percentage of
observations.
The lively discussion of our article has led us to consider a
compromise between the association framework proposed here
with another view of surrogates, termed auxiliary variables,
that might lead to greater consensus. If T is missing, auxiliary
variable methods would impute the value of T based on the
value of S. In this way, the composite endpoint of disease-free
survival (DFS) can be viewed as an imputation strategy by
replacing missing values of T with S. From the perspective of
auxiliary variables this is clearly biased, but in this setting
this might be reasonable for two reasons. First, S and T are
highly correlated so we might expect S to be a good prediction
of T. Second, DFS as an endpoint has a clinically meaning-
ful interpretation. Thinking of surrogate markers as auxiliary
information would seem to be a strategy that could keep the
discussants such as K and BIK happy because we still use the
real endpoint if it is available but would allow for information
in S to be utilized. If S was only weakly related to T then there
would be little gain in eﬃciency. By contrast, if S was strongly
related to T then there are potential gains in eﬃciency.
In closing, we would like to stress that if the goal is to iden-
tify surrogate endpoints that occur before the true endpoint
so that trials can be done more quickly, then this will neces-
sitate accepting a greater level of uncertainty. There are as-
pects based on the semicompeting risks framework that allow
for this, but by no means is this the only type of methodol-
ogy available. The question then becomes how much are you
willing to lean on the knowledge from biology and data from
other trials to help control this uncertainty. How to do this is
where the role of statistics is crucial.
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